Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vera Therapeutics Inc Cl A (VERA)

Vera Therapeutics Inc Cl A (VERA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,958,588
  • Shares Outstanding, K 63,928
  • Annual Sales, $ 0 K
  • Annual Income, $ -152,150 K
  • EBIT $ -270 M
  • EBITDA $ -278 M
  • 60-Month Beta 1.16
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.76

Options Overview Details

View History
  • Implied Volatility 67.38% (+3.50%)
  • Historical Volatility 55.26%
  • IV Percentile 35%
  • IV Rank 13.12%
  • IV High 228.19% on 05/30/25
  • IV Low 43.10% on 08/21/25
  • Expected Move (DTE 35) 7.74 (16.58%)
  • Put/Call Vol Ratio 0.13
  • Today's Volume 288
  • Volume Avg (30-Day) 1,430
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 21,939
  • Open Int (30-Day) 15,931
  • Expected Range 38.92 to 54.39

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.34
  • Number of Estimates 7
  • High Estimate -1.12
  • Low Estimate -1.62
  • Prior Year -0.72
  • Growth Rate Est. (year over year) -86.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
45.02 +4.02%
on 01/12/26
56.05 -16.45%
on 12/24/25
-1.47 (-3.04%)
since 12/16/25
3-Month
23.05 +103.17%
on 11/06/25
56.05 -16.45%
on 12/24/25
+16.32 (+53.49%)
since 10/16/25
52-Week
18.53 +152.73%
on 04/09/25
56.05 -16.45%
on 12/24/25
+14.05 (+42.86%)
since 01/16/25

Most Recent Stories

More News
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on January 5, 2026, the Compensation Committee of the Board of Directors of Vera Therapeutics...

VERA : 46.55 (+0.58%)
Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative...

VERA : 46.55 (+0.58%)
Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy

FDA assigned PDUFA target action date of July 7, 2026. If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN. Atacicept received FDA Breakthrough Therapy...

VERA : 46.55 (+0.58%)
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

BRISBANE, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative...

VERA : 46.55 (+0.58%)
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

BRISBANE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative...

VERA : 46.55 (+0.58%)
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on December 2, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics...

VERA : 46.55 (+0.58%)
Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors

BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments...

VERA : 46.55 (+0.58%)
Vera Therapeutics to Participate at Upcoming Investor Conferences

BRISBANE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments...

VERA : 46.55 (+0.58%)
Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit

BRISBANE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments...

VERA : 46.55 (+0.58%)
Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy

Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgAN ORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46%...

VERA : 46.55 (+0.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Vera Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Vera Therapeutics Inc. is based in SOUTH SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 51.90
2nd Resistance Point 50.68
1st Resistance Point 48.48
Last Price 46.55
1st Support Level 45.06
2nd Support Level 43.84
3rd Support Level 41.64

See More

52-Week High 56.05
Last Price 46.55
Fibonacci 61.8% 41.72
Fibonacci 50% 37.29
Fibonacci 38.2% 32.86
52-Week Low 18.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar